A multicenter phase IV clinical trial to examine the change of low-grade side effects after switch to Nilotinib from other tyrosine kinase inhibitors.

Phase 4

• Conditions: CML chronic phase

• Registration Number: JPRN-UMIN000008995
• Lead Sponsor: Tokyo CML Conference

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-09-27
• Study Completion: 2014-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who receive other therapy than TKI for CML 2) Patients participatinng in other clinical trials 3) Patients with bcr-ablT315I mutation 4) Patients who underwent stem cell transplantation 5) Patients with severe or uncontrolled coexisting illness 6) Patients with active malignancies 7) Patients with acute or chronic diseases in liver, pancreas, or severe kidney dysfunction, which is not atttributable to CML 8) Patients in pregnancy, lactation, or not be consent to control births 9) Patients who are assumed ineligible by the primary investigators or corresponding doctors.

Study & Design

• Study Type: Observational
• Study Design: Not specified